The Oscotec Clinical Trial called Study of Oral SKI-O-703, SYK Inhibitor, in Patients with Persistent and Chronic Immune Thrombocytopenia (ITP)

Sponsored by Oscotec Inc., this is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel dose study to evaluate the efficacy and safety of SKI-0-703, and SYK inhibitor, in patient’s with persistent and chronic ITP who have failed to respond (or relapsed after trying) other treatments. Patients in this study must have a platelet count less than 30,000μL on two separate occasion as at least 7 days apart. Participants will take part in three treatment groups for twenty weeks.

USA, Greece, Poland, Spain, Republic of Korea.


back to top

BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo